These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 29174711)

  • 1. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
    Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
    Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomy.
    Bargão Santos P; Lobo J; Félix A; Silva F; Manso RT; Costa JO; Lourenço B; Sequeira JP; Jerónimo C; Patel HHR; Henrique R
    Urol Oncol; 2020 Oct; 38(10):794.e17-794.e27. PubMed ID: 32278731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features.
    Ferreira C; Lobo J; Antunes L; Lopes P; Jerónimo C; Henrique R
    Virchows Arch; 2018 Oct; 473(4):443-452. PubMed ID: 30006753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer.
    Carvalho S; Freitas M; Antunes L; Monteiro-Reis S; Vieira-Coimbra M; Tavares A; Paulino S; Videira JF; Jerónimo C; Henrique R
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2127-2137. PubMed ID: 30105513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome.
    Cattrini C; Rubagotti A; Nuzzo PV; Zinoli L; Salvi S; Boccardo S; Perachino M; Cerbone L; Vallome G; Latocca MM; Zanardi E; Boccardo F
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1257-e1265. PubMed ID: 30170989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
    Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
    J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Twist-1, E-cadherin and EZH2 in Prostate Cancer: An Immunohistochemical Study.
    Abdelrahman AE; Arafa SA; Ahmed RA
    Turk Patoloji Derg; 2017; 1(1):198-210. PubMed ID: 28832071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
    Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
    Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy.
    Jacobs C; Tumati V; Kapur P; Yan J; Hong D; Bhuiyan M; Xie XJ; Pistenmaa D; Yu L; Hsieh JT; Saha D; Kim DW
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):729-35. PubMed ID: 24867541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
    Josefsson A; Wikström P; Egevad L; Granfors T; Karlberg L; Stattin P; Bergh A
    Scand J Urol Nephrol; 2012 Aug; 46(4):247-57. PubMed ID: 22452635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
    Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
    BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.
    Tretiakova MS; Wei W; Boyer HD; Newcomb LF; Hawley S; Auman H; Vakar-Lopez F; McKenney JK; Fazli L; Simko J; Troyer DA; Hurtado-Coll A; Thompson IM; Carroll PR; Ellis WJ; Gleave ME; Nelson PS; Lin DW; True LD; Feng Z; Brooks JD
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):264-70. PubMed ID: 27136741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nurses' Health Studies.
    Beca F; Kensler K; Glass B; Schnitt SJ; Tamimi RM; Beck AH
    Breast Cancer Res; 2017 Mar; 19(1):21. PubMed ID: 28253895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations of
    Ma SJ; Liu YM; Zhang YL; Chen MW; Cao W
    Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29089464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.
    Fantony JJ; Howard LE; Csizmadi I; Armstrong AJ; Lark AL; Galet C; Aronson WJ; Freedland SJ
    Biomark Med; 2018 Jul; 12(7):727-736. PubMed ID: 29902938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
    Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH
    Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.